Recent news releases
-
Sep 18, 2026 Apotex Health Corp. announces closing of upsized bought deal secondary offering
-
Sep 15, 2026 Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million
-
Sep 15, 2026 Apotex Health Corp. announces $750 million bought deal secondary offering
-
Aug 12, 2026 Apotex Announces First Quarter 2027 Results
-
Jul 17, 2026 Apotex Receives Investment Grade Issuer Rating from Morningstar DBRS and Announces Amended & Restated Credit Agreement
-
Jul 8, 2026 Apotex expands U.S. hospital portfolio with launch of generic Infuvite® Adult and Pediatric Injection
-
Jul 1, 2026 Apotex completes previously announced strategic transaction with Cumberland Pharmaceuticals
-
Jun 30, 2026 Apotex first to receive Health Canada approval for SEVMIA™, a generic semaglutide for chronic weight management
-
Jun 16, 2026 Apotex Health Corp. announces closing of upsized initial public offering and exercise of over-allotment option in full
-
Jun 10, 2026 Apotex Health Corp. files final prospectus and announces pricing of upsized initial public offering